Literature DB >> 8431928

Osteoclast inhibition for the treatment of bone metastases.

R E Coleman1, O P Purohit.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8431928     DOI: 10.1016/0305-7372(93)90028-p

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  8 in total

1.  Therapeutic use of bisphosphonates in oncology.

Authors:  R E Coleman
Journal:  BMJ       Date:  1994-11-05

Review 2.  Cancer-induced bone pain: Mechanisms and models.

Authors:  A N Lozano-Ondoua; A M Symons-Liguori; T W Vanderah
Journal:  Neurosci Lett       Date:  2013-09-25       Impact factor: 3.046

3.  Characterization of brain and bone-metastasizing clones selected from an ethylnitrosourea-induced rat mammary carcinoma.

Authors:  D G Hall; G Stoica
Journal:  Clin Exp Metastasis       Date:  1994-07       Impact factor: 5.150

Review 4.  Bisphosphonates and the treatment of bone disease in the elderly.

Authors:  A Johansen; M Stone; F Rawlinson
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

5.  The role of bisphosphonates in the treatment of bone metastases--the U.S. experience.

Authors:  H A Harvey; A Lipton
Journal:  Support Care Cancer       Date:  1996-05       Impact factor: 3.603

6.  Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line.

Authors:  P S Mackie; J L Fisher; H Zhou; P F Choong
Journal:  Br J Cancer       Date:  2001-04-06       Impact factor: 7.640

7.  High-dose intravenous pamidronate for metastatic bone pain.

Authors:  O P Purohit; C Anthony; C R Radstone; J Owen; R E Coleman
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

8.  Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD).

Authors:  P J Ling; R P A'Hern; J R Hardy
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.